Topics

Sintilimab Combined With Anlotinib in Third Line or Beyond Among Advanced SCLC Patients

2019-08-18 20:09:36 | BioPortfolio

Summary

Small cell lung cancer (SCLC) accounts for 10-15% of lung cancer. More than 70% of SCLC patients are diagnosed with advanced stage initially. SCLC is highly chemo-sensitive, the first-line treatment is platinum-containing double-drug chemotherapy. Although the objective response rate (ORR) of first-line chemotherapy is as high as 60-80%, the duration of response is very short, and there is little effective follow-up treatment. The outcome of SCLC patients is poor with an overall survival (OS) of about 10 months.

In August 2018, the FDA approved Nivolumab as a third-line treatment for advanced SCLC patients, which is the only immunotherapeutic drug approved for SCLC till now. Sintilimab is another PD-1 inhibitor produced by China and has been approved by cFDA for lymphoma. Anlotinib is a novel multi-target tyrosine kinase inhibitor (TKI) with effect of anti-tumor angiogenesis and tumor growth inhibition. The results of ALTER1202 show that compared with placebo, Anlotinib single-agent as three-line treatment in advanced SCLC was effective, the median progression free survival (PFS) were 4.1 versus 0.7 months, respectively (P < 0.0001).

Immunotherapy combined with anti-angiogenic therapy has been proven effective and tolerable in non-small cell lung caner (NSCLC), while its efficacy and safety in SCLC has not been reported. Therefore, the investigators conduct this study to evaluate the efficacy and safety of Sintilimab combined with Anlotinib versus Anlotinib alone in third line or beyond among advanced SCLC patients.

Study Design

Conditions

Small-cell Lung Cancer

Intervention

Sintilimab, Anlotinib

Location

Henan Cancer Hospital
Zhengzhou
Henan
China
450000

Status

Recruiting

Source

Henan Cancer Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-08-18T20:09:36-0400

Clinical Trials [5485 Associated Clinical Trials listed on BioPortfolio]

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

This is an efficacy and safety study of Anlotinib combined with Sintilimab (IBI 308) in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have received first-...

S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

The purpose of this study is to assess the efficacy and safety of S1 combination with Anlotinib in patients with small cell lung cancer whose cancer has progression or recurrence after at ...

Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer

Anlotinib has been approved as a third-line treatment for advanced non-small-cell lung cancer. A phase II clinical studies of small cell lung cancer (ALTER-1210) also showed that, compared...

Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

This is a single-arm, open-label and exploratory clinical study of Anlotinib Hydrochloride Capsules combined with Sintilimab injection in the treatment of advanced Hepatocellular Carcinoma...

Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer

Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor c...

PubMed Articles [32504 Associated PubMed Articles listed on BioPortfolio]

Body mass index (BMI), BMI change, and overall survival in small cell and non-small cell lung cancer patients: a pooled analysis of the International Lung Cancer Consortium.

The relationships between morbid obesity, changes in body mass index (BMI) prior to cancer diagnosis, and lung cancer outcomes by histology (small-cell lung cancer (SCLC) and non-SCLC (NSCLC)) have no...

Mechanism of decorin protein inhibiting invasion and metastasis of non-small cell lung cancer.

To detect the protein level of Decorin in non-small cell lung cancer (NSCLC) patients, and to study the mechanism of Decorin inhibiting invasion and metastasis of non-small cell lung cancer from the p...

Regulatory Network Analysis to Reveal Important miRNAs and Genes in Non-Small Cell Lung Cancer.

Lung cancer has high incidence and mortality rate, and non-small cell lung cancer (NSCLC) takes up approximately 85% of lung cancer cases. This study is aimed to reveal miRNAs and genes involved in th...

Immune Cell Infiltration May be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.

While most small cell lung cancer (SCLC) patients die within a few months of diagnosis, a sub-group of patients survive for many years. Factors determining long-term survivorship remain largely unknow...

p38 MAP kinases: plausible diagnostic and prognostic serum protein marker of non small cell lung cancer.

p38 MAPK signaling molecules plays a dual role in cancer, both progression and suppression. Elevated expression of p38α was reported in lung cancer tissue in rat model. Our objective was to explore t...

Medical and Biotech [MESH] Definitions

Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.

A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.

A cell adhesion molecule that contains extracellular immunoglobulin V and C2 domains. It mediates homophilic and heterophilic cell-cell adhesion independently of calcium, and acts as a tumor suppressor in NON-SMALL-CELL LUNG CANCER (NSCLC) cells. Its interaction with NATURAL KILLER CELLS is important for their cytotoxicity and its expression by MAST CELLS plays a role in their interaction with neurons; it may also function in synapse assembly, nerve growth and differentiation.

More From BioPortfolio on "Sintilimab Combined With Anlotinib in Third Line or Beyond Among Advanced SCLC Patients"

Quick Search

Relevant Topics

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Searches Linking to this Trial